BRAF and melanoma: This inhibitor exhibited a strong antitumor activity on BRAF(V600E)-harboring melanoma in vitro and in vivo[21], and its analog with more favorable pharmacokinetics, vemurafenib (PLX4032), was first approved for treating advance melanomas and then for other cancers with BRAF(V600E) mutation [Table 1][24,132,133].